Skip to main content

Federal appeals court revives lawsuit saying FDA overstepped on anti-ivermectin messaging

A federal appeals court has ruled that a lawsuit against the Food and Drug Administration for advocating against Ivermectin use can proceed.

A federal appeals court is reviving a lawsuit against the Food and Drug Administration for discouraging ivermectin use during the COVID-19 pandemic.

The three doctors behind the suit are claiming the agency overstepped its bounds by aggressively messaging against the medication ivermectin for the treatment of COVID-19 symptoms.

The federal appeals court on Friday overturned a lower court's ruling that the lawsuit could not continue.

FDA APPROVES FIRST PILL TO TREAT POSTPARTUM DEPRESSION

The doctors allege that the FDA harmed their reputations by publicizing medical advice against the drug — an action that would fall outside its prerogative to inform, not prescribe. 

The federal appeals court found that there was a basis for the lawsuit to move forward.

"[The] FDA is not a physician. It has authority to inform, announce, and apprise—but not to endorse, denounce, or advise," Judge Don Willett wrote. "The Doctors have plausibly alleged that FDA’s Posts fell on the wrong side of the line between telling about and telling to."

TORNADO DAMAGE TO NORTH CAROLINA PFIZER PLANT UNLIKELY TO CAUSE SIGNIFICANT DRUG SUPPLY IMPACTS, FDA SAYS

Ivermectin became the subject of intense debate after some doctors began prescribing the drug as a treatment for COVID-19.

Critics characterized the drug as "cattle" or "horse medication," citing its use to treat parasites in animals. However, the drug is also approved for human use to treat parasites, skin conditions and other ailments. 

Self-administering the drug can be dangerous and result in accidental poisoning. 

 GET FOX BUSINESS ON THE GO BY CLICKING HERE

The FDA advocated against the medication during the pandemic, frequently employing the slogan "You are not a horse!"

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.